Crinetics Pharmaceuticals

CRNXApproved

San Diego, United Statescrinetics.com

Crinetics Pharmaceuticals is building a premier, endocrine-rooted global pharmaceutical company dedicated to improving the lives of patients with endocrine disorders. Founded by scientists with a proven track record in GPCR drug discovery, the company has advanced a pipeline of novel, oral nonpeptide therapies targeting significant unmet needs. With a lead program in Phase 3 for acromegaly and a growing pipeline, Crinetics is positioned to become a leader in next-generation endocrine care.

Market Cap

$3.7B

Focus

Small Molecules

CRNX · Stock Price

USD 35.57+16.61 (+87.61%)

Historical price data

AI Company Overview

Technology Platform

Specialized platform for the discovery and development of selective, oral, nonpeptide small molecule therapeutics targeting G-protein coupled receptors (GPCRs) within the endocrine system.

Pipeline Snapshot

18 drugs in pipeline, 5 in Phase 3

Drug	Indication	Stage
Paltusotine + Placebo	Acromegaly	Phase 3
Paltusotine + Placebo	Carcinoid Syndrome	Phase 3
Paltusotine + Placebo	Acromegaly	Phase 3
Atumelnant + Placebo	Congenital Adrenal Hyperplasia	Phase 3
Atumelnant + Placebo	Congenital Adrenal Hyperplasia	Phase 2/3

Funding History

Total raised: $148.3M

IPO$100.8MJefferiesJul 19, 2018

Series B$42.5MPerceptive AdvisorsJun 15, 2016

Series A$5M5AM VenturesJun 15, 2010

FDA Approved Drugs

PALSONIFYNDASep 25, 2025

Opportunities

Major near-term opportunity with the potential first oral maintenance therapy for acromegaly (paltusotine).

Significant expansion into carcinoid syndrome and other endocrine disorders (Cushing's, CAH) with a pipeline of novel oral therapies.

Building a fully integrated, leading global endocrine pharmaceutical company.

Risk Factors

Clinical and regulatory risk remains for lead asset paltusotine.

Execution risk in transitioning to a commercial-stage company and competing against established injectable therapies.

High dependency on the success of a single lead program in the near term.

Competitive Landscape

Competes against established injectable somatostatin analogs (Novartis, Ipsen) and newer oral therapies in acromegaly and carcinoid syndrome. Differentiation is based on oral convenience, receptor selectivity, and a specialized platform for nonpeptide GPCR drug discovery.

Publications

Patents

Pipeline

FDA Approvals